Femprox

Femprox®

Alprostadil A topical hormone analogue in clinical trials for treating ♀ sexual dysfunction. See Sexual dysfunction. .
References in periodicals archive ?
Main products and pipelines include Vitaros, Fispemifene, RayVa and Femprox.
Femprox Cream: A proprietary product currently in Phase 2 clinical development for female sexual dysfunction.
has announced that CJ Corporation, one of the top five pharmaceuticals companies in South Korea, has licensed Femprox for Korea.
As a response to their plight, the drug company NexMed developed Femprox, a lotion which gives "warm and pleasant sensations" when rubbed onto the genital area.
Many of the drugs currently in development - VasoFem, Alista, Femprox - act in the same way as Viagra by engorging the tissues of the genital area.
an emerging international pharmaceutical and medical device company, is developing 1) Alprox-TD and Femprox, topically-applied treatments for male and female sexual dysfunction; and 2) Viratrol, a non-invasive, hand-held device for treating oral and genital herpes.
has reported the Phase I clinical trial results on its Femprox topical treatment for female sexual dysfunction ("FSD"), conducted at the Robert Wood Johnson Medical School ("RWJMS") in New Brunswick, New Jersey.
Apricus Bio") (Nasdaq: APRI) backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT([R]) drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, "Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.
Marc Gittelman, MD, FACS, Director of the Miami Center for Sexual Health and a NexMed consultant, will make two Femprox presentations at the Annual Meeting of the International Society for the Study of Women's Sexual Health ("ISSWSH"), which takes place October 27-30, 2005 in Las Vegas, NV.
Nasdaq: NEXM), a developer of innovative products based on the NexACT([R]) drug delivery technology, today confirmed that previously unpublished clinical data on Femprox, the Company's topical treatment for female sexual arousal disorder, was published in the August 2008 issue of The Journal of Sexual Medicine.
Female Sexual Arousal Disorder (FSAD) Product: Femprox
Femprox is applied topically and incorporates alprostadil, a vasodilator, with the NexACT(R) permeation technology.